Genetic and epidemiological description of an outbreak of circulating vaccine-derived polio-virus type 2 (cVDPV2) in Angola, 2019–2020

Morais, Alda; Morais, Joana; Félix, Miguel; Neto, Zoraima; Madaleno, Valódia; Umar, Abubakar Sadiq; Panda, Nirakar; Lemma, Fekadu; Chivale, José Alexandre Lifande; Cavalcante, Danielle Graça; Davlantes, Elizabeth; Ghiselli, Margherita; Espinosa, Catherine; Whiteman, Ari; Iber, Jane; Henderson, Elizabeth; Bullard, Kelley; Jorba, Jaume; Burns, Cara C.; Diop, Ousmane M.; Gumede, Nicksy; Seakamela, Lerato; Howard, Wayne; Frawley, Alean

doi:10.1016/j.vaccine.2023.02.035

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was well stated that "without global eradication, there is a risk of re-infection from the importation and spread of wild poliovirus or VDPV, or the emergence and circulation of VDPV" [64]. It is also important to improve the surveillance sensitivity and completeness of AFP case investigations for full detection and interruption of viral transmission [65].…”

Section: Eradication and Control Of Cvdpvmentioning

confidence: 99%

Infezioni in Medicina

2023

Infez Med

View full text Add to dashboard Cite

Poliomyelitis is caused by Poliovirus, a member of a large group of enteroviruses. Vaccine-derived polioviruses (VDPVs) stem from mutated live poliovirus, which is contained in the Oral Polio Virus vaccine (OPV). In addition, the emergence of VDPV is one of the global challenges for the eradication of poliomyelitis. VDPVs continue to affect different parts of the world; 1081 cases occurred in 2020 and 682 cases in 2021. There are several reasons that may have caused the increase in circulating vaccine-derived poliovirus (cVDPV) after the "switch" from the trivalent to the bivalent oral polio vaccine. One reason is the low vaccination rate among the targeted population, which has been further aggravated by the COVID-19 pandemic. Several strategies could control the spread of VDPV including the use of the monovalent OPV (mOPV-2). The risk of VDPV can be minimized through increased immunization rates and the use of safer vaccine alternatives. The global effort to eradicate polio has made significant progress over the years, but continued vigilance and investment in immunization programs are needed to achieve the ultimate goal of a polio-free world.

show abstract

Section: Eradication and Control Of Cvdpvmentioning

confidence: 99%